An intraosseous malignant peripheral nerve sheath tumor of the lumbar spine without neurofibromatosis: Case report and review of the literature

KAYO SUZUKI¹, TAKETOSHI YASUDA¹, TAKESHI HORI², KENTÅ WATANABE¹, MASAHIKO KANAMORI³ and TOMOATSU KIMURA¹

¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama City, Toyama 939-0194; ²Department of Orthopaedic Surgery, Iiyama Red Cross Hospital, Iiyama City, Nagano 389-2295; ³First Department of Human Science, Faculty of Medicine, University of Toyama, Toyama City, Toyama 939-0194, Japan

Received September 11, 2013; Accepted March 4, 2014

DOI: 10.3892/ol.2014.1987

Abstract. A malignant peripheral nerve sheath tumor (MPNST) is defined as any malignant tumor that develops or differentiates from cells in the peripheral nerve sheath. This tumor is commonly associated with neurofibromatosis type 1 (NF1) and previous radiotherapy treatment. Primary intraosseous MPNSTs are extremely rare and a case of the lumbar spine in a patient without NF1 is reported in the present study, with a review of the intraosseous MPNST literature. A 45-year-old female presented with a 1-month history of severe lower back pain and pain radiating to the left leg. A total en bloc spondylectomy of L4 was performed. The postoperative histopathological diagnosis was MPNST with deletion of NF1, confirmed by dual-color fluorescence in situ hybridization (FISH) analysis. The tumor recurred 1 month following the surgery. Although adjuvant chemotherapy was administered, the patient succumbed due to intramedullary dissemination and carcinomatous meningitis 8 months following the initial consultation. NF1 deletion by FISH analysis may be particularly useful in distinguishing MPNST from other high-grade malignancies with overlapping morphological features.

Introduction

A malignant peripheral nerve sheath tumor (MPNST) is a rare tumor that accounts for ≤5% of soft-tissue sarcomas, often arising from Schwann cells (1). Approximately 50% of MPNSTs occur in patients with neurofibromatosis type 1 (NF1), and 10% of these are radiation-induced, while the remainder affect individuals without a known genetic predisposition. The most common locations for MPNSTs are the trunk, extremities and head and neck (2). Isolated studies have reported the development of MPNST following irradiation and primary or metastatic intradural MPNST of the spine (3-5). Spinal MPNST usually develops from spinal nerve roots and causes secondary bony changes. However, primary intraosseous MPNST is extremely rare and, to the best of our knowledge, only five cases in the spine have been reported in the literature (6-10). As the tumors have a high malignancy and invasive natural course with a common recurrence and distant metastases, they have a poor prognosis, even with gross total resection.

An additional case of intraosseous MPNST of the lumbar spine in a patient without NF1 is presented in the current study, and the relevant literature on intraosseous MPNST is reviewed. The study was conducted following a clinical research review by the ethics committee of Toyama University Hospital (Toyama City, Japan). Informed consent was obtained from the patient, who was advised that the data from the case would be submitted for publication.

Case report

Case summary. A 45-year-old female presented with a 1-month history of severe lower back pain and pain radiating to the left leg. No ‘café au lait’ spots or neurofibromas were present and the patient confirmed there was no family history of NF1. The neurological examination revealed a decreased sensation to a pin prick in the left L4 area. There was no obvious motor weakness of the leg, and bladder and bowel dysfunction was evident. Plain radiographs of the lumbar spine showed an osteolytic lesion at the L4 vertebral body. Computed tomography revealed compression of the spinal canal resulting from destruction of the posterior elements of L4 (Fig. 1). Magnetic resonance imaging (MRI) showed a destructive lesion and extradural tumor at the L4 level with dural compression. The lesion extending from the L4 vertebral body to bilateral
pedicles showed intermediate signal intensity on T1-weighted images (Fig. 2A and C), and it was heterogeneous with mixed high and intermediate signal intensities on T2-weighted images (Fig. 2B and D). No other tumors were identified.

As the paralysis progressed rapidly, decompressive laminectomies and extradural tumor resection were performed. At the same time, posterior spinal fusion with instruments including a percutaneous pedicle screw system (Mantis, Stryker Japan Co., Tokyo, Japan) was performed for maintenance of spinal stability and prevention of tumor dissemination. The tumor appeared slightly adherent to the dura. The tumor mass was not obviously connected with the bilateral L4 spinal nerve roots or the dura. The boundary between the tumor and the L4 vertebral body was unclear. Histologically, the tumor consisted of coagulation necrosis and sheets of tumor cells with alternating areas of hyper- and hypocellularity. The majority of the tumor cells were atypical spindle cells. The spindle cells exhibited mitotic figures and pleomorphism. Immunohistochemically, the spindle cells were positive for vimentin and smooth muscle actin and negative for S-100, epithelial membrane antigen (EMA) and cluster of differentiation 34 (CD34). The histological diagnosis was undifferentiated pleomorphic sarcoma. Postoperatively, the symptoms of the patient were dramatically relieved. However, they recurred two weeks following the surgery, and the patient presented with progressive hypoesthesia and motor weakness in the legs. A total en bloc spondylectomy was performed according to a previous study (Fig. 3) (11). Briefly, all posterior elements of the spine (the spinous process, the superior and inferior articular processes, the transverse process and the pedicle) were removed in one section using a posterior approach. Subsequently, the anterior elements of the spine (the vertebral body and psoas muscle) were removed en bloc at the coincident level of the posterior halves using an anterior midline transperitoneal approach. To maintain stability of the tumor resection, anterior and posterior instrumented fixation was performed.

Although multidrug adjuvant chemotherapy (30 mg/m² doxorubicin, 1.5 g/m² ifosfamide and 300 mg/m² dacarbazine; 3 days) was administered following the second surgery (12), the patient succumbed to intramedullary dissemination and carcinomatous meningitis 8 months following the initial consultation.

Pathological study. The second postoperative histopathological examination revealed a densely cellular area composed of spindle cells with a fascicular growth pattern and coagulation necrosis. Each of the spindle cells exhibited irregular contours with abundant gross cellular atypia, mitotic figures and pleomorphism (Fig. 4). On immunohistochemical staining, the tumor cells were positive for vimentin and bcl-2, focally positive for EMA, and negative for AE1/AE3, desmin, S-100, CD99 and CD34.

Fluorescence in situ hybridization (FISH) analysis. FISH was performed on an unstained, paraffin-embedded tissue section using the Dual Color, Break Apart Rearrangement Probe (Kreatech Diagnostics, Amsterdam, Netherlands) according to the manufacturer's instructions. Hybridization signals were assessed in 200 interphase nuclei with strong, well-delineated signals and distinct nuclear borders by two individuals, as previously described (13). Dual color FISH analysis involving chromosome 17q showed that >10% of the cells from the tumor showed the deletion signal pattern of one red (NF1 region probe on 17q11) and two green [myeloperoxidase (MPO) gene region on 17q22 as the control probe), demonstrating a deletion of the NF1 gene (Fig. 5). These histopathological and cytogenetic findings confirmed the diagnosis of MPNST with focal epithelioid features.

Discussion

MPNSTs are rare malignant tumors arising from peripheral nerve sheath cells. These tumors typically present as an enlarging mass originating from a peripheral nerve root of the trunk (~50%), in the extremities (~30%), or the head and neck region (~20%) (2). Secondary bony infiltration in a paraspinal MPNST is a well-known entity. However, a primary intraosseous MPNST is extremely rare. An intraosseous MPNST may develop from minute, mainly unmyelinated nerve roots that accompany nutrient vessels and ramify within Volkmann's canals and bone marrow (14-16). To the best of our knowledge, only 19 cases of intraosseous MPNSTs, including the present study, have been reported in the literature to date (Table I) (6-10,17-29). There were nine male and 10 female patients, and the age at diagnosis ranged from 4-76 years. A total of eight of the 19 cases (42%) occurred in the mandible or maxilla and six cases (32%) involved a vertebral body of the spine. Although <50% of MPNSTs arise in patients with NF1 (29), intraosseous MPNST cases were not associated with the hereditary NF1 syndrome, except for one case. The case of the present study was also not associated with NF1.

Due to a wide morphologic spectrum and lack of specific markers, the diagnosis of intraosseous MPNST is extremely difficult, particularly in a case lacking the manifestations of NF1 and classic histopathological features. High-grade MPNSTs may resemble other malignancies, including fibrosarcoma, synovial sarcoma and malignant fibrous histiocytoma. In the present study, although the initial
The histological diagnosis was an undifferentiated pleomorphic sarcoma, the histological diagnosis of the recurrent mass was MPNST with positive immunohistochemistry for vimentin and bcl-2, focally positive for EMA, but negative for AE1/AE3, desmin, S-100, CD99 and CD34. Numerous antigens are useful in the identification of nerve sheath differentiation, including

Table I. Summary of reported cases of intraosseous MPNST.

| Case (ref.) | Age (years)/Gender | Location | NF1 | Surgery | Adjuvant therapy | Outcome (months) |
|-------------|--------------------|----------|-----|---------|------------------|-----------------|
| 1 (17)      | 55/M               | Ulna     | -   | CR      | None             | NED (20)        |
| 2 (18)      | 65/F               | Mandible | -   | NA      | NA               | NA              |
| 3 (19)      | 65/M               | Mandible | -   | Resection | RT             | AWD (NA): recurrence |
| 4 (20)      | 4/F                | Mandible | NA  | NA      | NA               | NA              |
| 5 (21)      | 28/M               | Ulna     | -   | NA      | NA               | NA              |
| 6 (22)      | 11/F               | Mandible | -   | Resection | None         | NED (6)         |
| 7 (23)      | 76/F               | Mandible | -   | NA      | NA               | NA              |
| 8 (24)      | 61/F               | Maxilla  | -   | NA      | NA               | NA              |
| 9 (25)      | 47/F               | Maxilla  | -   | Resection | RT, CT        | DOD (22)        |
| 10 (26)     | 50/M               | Mandible | -   | NA      | RT               | DOD (12)        |
| 11 (27)     | 28/M               | Femur    | -   | Resection | None         | DOD (1): pulmonary metastasis |
| 12 (28)     | 26/M               | Femur    | -   | Resection | CT            | DOD (15): pulmonary metastasis |
| 13 (29)     | 29/M               | Ulna     | -   | Resection | None         | DOD (36): pulmonary metastasis |
| 14 (6)      | 40/F               | C2       | NA  | STR, PSF | None         | DOD (12): pulmonary metastasis |
| 15 (7)      | 59/F               | T3       | NA  | STR, PSF | RT, CT       | AWD (46): bone metastasis |
| 16 (8)      | 75/F               | T7       | -   | STR, PSF | RT            | DOD (6): pulmonary metastasis |
| 17 (9)      | 41/M               | C7       | -   | CR, PSF | CT            | NED (24)        |
| 18 (10)     | 75/M               | L3       | -   | STR     | NA            | NA              |
| 19 (present)| 45/F               | L4       | -   | STR, PSF | CT            | DOD (8): carcinomatous meningitis |

MPNST, malignant peripheral nerve sheath tumor; NF1, neurofibromatosis type 1; M, male; F, female; C, cervical; T, thoracic; L, lumbar; CR, complete resection; NA, not available; STR, subtotal resection; PSF, posterior spinal fusion; RT, radiotherapy; CT, chemotherapy; NED, no evidence of disease; AWD, alive with disease; DOD, dead of disease.

Figure 2. MRI of the lumbar spine. (A and C) T1- and (B and D) T2-weighted MRI of the lumbar spine in the (A and B) sagittal and (C and D) axial planes. The MRI shows L4 vertebral collapse and an extradural mass compressing the dura mater. The lesion extending from the L4 vertebral body to bilateral pedicles shows intermediate signal intensity on T1-weighted images and heterogeneous with mixed high and intermediate signal intensities on T2-weighted images. MRI, magnetic resonance imaging.
S-100 protein, Leu-7 and myelin basic protein. The protein S-100 is the most commonly used antigen for neural differentiation, and it can be identified in ~50% of MPNSTs, although the staining is typically focal and limited to a small number of cells. As encountering an MPNST with a strong and diffuse immunoreactivity for the S-100 protein is uncommon, such a staining pattern always indicates that other benign diagnoses should be reconsidered, particularly cellular schwannoma. The proteins myelin basic protein and Leu-7 have been identified in ~40 and ~50% of MPNSTs, respectively (30).

The molecular pathogenesis of MPNST remains poorly understood. In contrast to numerous other sarcomas, there is no pathognomonic chromosomal translocation and conventional cytogenetic studies typically yield complex, often near-triploid karyotypes without specific aberrations (1). However, loss involving chromosome 17q, the site of the NF1, has been detected in 25-50% of reported sporadic and NF1-associated cases, often in the form of chromosomal monosomy. Similarly, NF1 deletion in FISH analysis may aid in distinguishing MPNSTs from other high-grade malignancies with overlapping morphological features. Perry et al (31) demonstrated that NF1 deletions were detectable in 76% of sporadic and NF1-associated MPNSTs by FISH analysis and observed in five out of six high-grade MPNSTs that lacked S-100 protein immunoreactivity, which is considered to be a significant marker for Schwann cells. Additionally, it has been reported that of eight cases with MPNST, NF1 deletion was detected within the S-100-positive cellular populations of four MPNSTs (50%), while S-100-negative nuclei were observed in all eight MPNSTs. These results indicated the prevalence of NF1 deletion in MPNSTs, regardless of S-100 protein expression (32). In the case of the present study, immunohistochemistry for S-100 protein was negative in tumor cells, and NF1 deletion by FISH was simultaneously detected. Therefore, MPNST in the present case was believed to be a high-grade malignancy from the viewpoint of the S-100 protein-negative cells, which represent dedifferentiated Schwann cells.
Surgical resection is the treatment of choice for MPNSTs. Complete tumor resection with negative margins remains the most effective treatment. A study by Wong et al (33) reported that the rate of en bloc resection in 128 patients with MPNSTs was 83% and, of these patients, only 48% had negative surgical margins. However, en bloc resection is often extremely complicated in cases of spinal MPNST due to the surrounding spinal cord, dura mater and large blood vessels. In previous studies, four out of the five vertebral MPNSTs underwent subtotal resection, and the outcomes of three cases included two who succumbed to disease and one who remained with disease (Table 1). Adjuvant radiation therapy to a dose of >60 Gy improves local control of this disease (34). The effectiveness of chemotherapy for MPNST remains controversial. Certain success has been reported with doxorubicin use alone or in combination with other drugs (35). However, the effects of chemotherapy and radiotherapy are unclear.

In conclusion, the current study presents a case of intraosseous MPNST arising in a lumbar vertebra. Although en bloc resection of the tumor and adjuvant chemotherapy were performed, the patient succumbed to carcinomatous meningitis. Since the outcome remains poor, further studies on genetic therapy of the tumor based on its molecular pathogenesis are required.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research [C] 24592227 (KAKENHI). The authors would like to thank Professor Tadashi Hasegawa, Department of Surgical Pathology, Sapporo Medical University (Japan) for providing excellent FISH analysis. The abstract was presented at the International Society of Limb Salvage 17th General Meeting (abstract no. 396).

References

1. Weiss SW and Goldblum JR (eds): Malignant tumors of the peripheral nerves. In: Enzinger and Weiss's Soft Tissue Tumors. 5th edition. Mosby, St. Louis, MO, pp903-916, 2007.
2. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM and Hilstrup DM: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57: 2006-2021, 1986.
3. Amin A, Saifuddin A, Flanagan A, Patterson D and Lehovsky J: Radiotherapy-induced malignant peripheral nerve sheath tumor of the cauda equina. Spine (Phil Pa 1976) 29: E402-E405, 2004.
4. Baek WS, Pytel P, Undevia SD and Rubeiz H: Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor. J Neurooncol 74: 183-185, 2005.
5. Acharya R, Bhalla S and Sehgal AD: Malignant peripheral nerve sheath tumor of the cauda equina. Neurol Sci 22: 267-270, 2001.
6. Khan RJ, Ashger J, Sohail MT and Chughtai AS: Primary intraosseous malignant peripheral nerve sheath tumor: a case report and review of the literature. Pathology 30: 237-241, 1998.
7. Gnanalingham K, Bhattacharjee S and O'Neil K: Intraosseous malignant peripheral nerve sheath tumor (MPNST) of the thoracic spine: a rare case of spinal cord compression. Spine (Phil Pa 1976) 29: E402-E405, 2004.
8. Miyakoshi N, Nishikawa Y, Shimada Y, et al: Intraosseous malignant peripheral nerve sheath tumor with focal epithelioid differentiation of the thoracic spine. Neurul India 55: 64-66, 2007.
9. Moore SJ, Lee JK, Seo BR, et al: An intraosseous malignant peripheral nerve sheath tumor of the cervical spine: a case report and review of the literature. Spine (Phil Pa 1976) 33: E712-E716, 2008.
10. Patnaik A, Mishra SS, Senapati SB, et al: Primary intraosseous malignant peripheral nerve sheath tumor of spine with a giant paraspinal and retropulsed subcutaneous extension. Surg Neurol 77: 1257-1263, 2012.
11. Kawahara N, Tomita K, Murakami H, et al: Total en bloc spondylectomy of the lower lumbar spine: a surgical techniques of combined posterior-anterior approach. Spine (Phila Pa 1976) 36: 74-82, 2011.
12. Elias A, Ryan L, Sulkes A, et al: Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7: 1208-1216, 1989.
13. Yasuda T, Perry KD, Nelson M, et al: Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature. Hum Pathol 40: 341-348, 2009.
14. Nannapaneni R and Sinar EJ: Intraosseous schwannoma of the cervical spine. Br J Neurosurg 19: 244-247, 2005.
15. Chang CJ, Huang JS, Wang YC and Huang SH: Intraosseous schwannoma of the fourth lumbar vertebra: case report. Neurosurgery 43: 1219-1222, 1998.
16. Polkey CE: Intraosseous neurilemmoma of the cervical spine causing paraparesis and treated by resection and grafting. J Neurol Neurosurg Psychiatry 38: 776-781, 1975.
17. Peers JH: Primary intramedullary neurogenic sarcoma of the ulna. Report of a case. Am J Pathol 10: 81-820, 1934.
18. Bell WE: Neurogenic sarcoma of the mandible: report of a case. J Am Dent Assoc 23: 1351-1356, 1936.
19. Devore DT and Waldron CA: Malignant peripheral nerve tumors of the oral cavity. Review of the literature and report of a case. Oral Surg Oral Med Oral Pathol 14: 56-68, 1961.
20. Ingram FL: Radiology of tumours of the mandible. Clin Radiol 13: 47-53, 1962.
21. Bose KS, Thakur S, Chakraborty S and Banerjee S: Intra-ossus malignant schwannoma. J Indian Med Assoc 54: 328-329, 1970.
22. Glass RT and Livingston RJ: Malignant epithelioid schwannoma in a child: a case report. Quintessence Int Dent Dig 15: 1047-1450, 1984.
23. Shirasuna K, Fukuda Y, Kitamura, et al: Malignant schwannoma of the mandible. Int J Oral Maxillofac Surg 15: 772-776, 1986.
24. Kameyama Y, Maeda H, Nakane S, et al: Malignant schwannoma of the maxilla in a patient without neurofibromatosis. Histopathology 11: 1205-1208, 1987.
25. Urade M, Fujimoto Y, Ogura T and Matsuya T: Malignant schwannoma and melanoma occurring in the maxilla. J Osaka Univ Dent Sch 30: 153-156, 1990.
26. Bailey JW, Abemayor E, Andrews JC, et al: Malignant nerve sheath tumors of the head and neck: a combined experience from two university hospitals. Laryngoscope 101: 1044-1049, 1991.
27. Bullock MJ, Bedard YC, Bell RS and Kandel R: Intraosseous malignant peripheral nerve sheath tumor: report of a case and review of the literature. Arch Pathol Lab Med 11: 367-370, 1995.
28. Perry DG, Sauser DD and Gordon MD: Intraosseous malignant peripheral nerve sheath tumor in a patient with neurofibromatosis. Skeletal Radiol 27: 346-349, 1998.
29. Kondi TK, Erakar A, Yildiz HY, Saglik Y and Ereksiul S: Intraosseous malignant peripheral nerve sheath tumor with local recurrence, lung metastases and death. Skeletal Radiol 33: 223-225, 2004.
30. Wick MR, Swanson PE, Scheithauer BW and Manivel JC: Malignant peripheral nerve sheath tumor: An immunohistochesmical study of 62 cases. Am J Clin Pathol 87: 425-433, 1987.
31. Perry A, Kunz SN, Fuller CE, et al: Differential NF1, p16, and EGFR patterns by interphase cytogenetic (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 61: 702-709, 2002.
32. Perry A, Roth KA, Banerjee R, et al: NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 159: 57-61, 2001.
33. Wong WW, Hirose T, Scheithauer BW, et al: Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42: 351-360, 1998.
34. Anghileri M, Miceli R, Fiore M, et al: Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 107: 1065-1074, 2006.
35. Goldman RL, Jones SE and Heusinkveld RS: Combination chemotherapy of metastatic malignant schwannoma with vincristine, adriamycin, cyclophosphamide, and imidazole carboxamide: a case report. Cancer 39: 1955-1958, 1977.